← All Cns Pharmaceuticals, INC filings

Cns Pharmaceuticals, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
CNSP
Cns Pharmaceuticals, INC
DEFA14A: CNS Pharma Corrects Proxy Card for Annual Meeting
CNS Pharmaceuticals, Inc. filed a supplement to its proxy statement to correct an error on the proxy card related to the 'say-on-pay' frequency vote for its upcoming November 17, 2025 annual meeting.
NASDAQ
CNSP
Cns Pharmaceuticals, INC
DEF: CNS Pharma Seeks Share Increase, Board Re-election
CNS Pharmaceuticals, Inc. will hold its Annual Meeting on November 17, 2025, seeking stockholder approval for key proposals including a significant increase in authorized shares and re-election of directors.
NASDAQ
CNSP
Cns Pharmaceuticals, INC
DEFR14A: CNS Pharmaceuticals Revises Reverse Stock Split Proposal, Opts for Cash Payments for Fractional Shares
CNS Pharmaceuticals has amended its reverse stock split proposal to provide cash payments instead of fractional shares to stockholders.
NASDAQ
CNSP
Cns Pharmaceuticals, INC
DEF 14A: CNS Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split and Warrant Repricing to Maintain Nasdaq Listing
CNS Pharmaceuticals is holding a special meeting to seek stockholder approval for a reverse stock split and warrant repricing to comply with Nasdaq listing requirements.
NASDAQ
CNSP
Cns Pharmaceuticals, INC
DEF 14A: CNS Pharmaceuticals Seeks Stockholder Approval for Reverse Stock Split, Share Increase, and Warrant Repricing
CNS Pharmaceuticals is asking stockholders to approve several key proposals at its upcoming annual meeting, including a reverse stock split, an increase in authorized shares, and the repricing of certain warrants.